"Toluidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any of three isomeric compounds (ortho-, meta-, and para-) containing a benzene ring with a methyl and amino group attached to it. They are suspected CARCINOGENS.
| Descriptor ID |
D014052
|
| MeSH Number(s) |
D02.092.146.859 D02.455.426.559.389.832.559
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Toluidines".
Below are MeSH descriptors whose meaning is more specific than "Toluidines".
This graph shows the total number of publications written about "Toluidines" by people in this website by year, and whether "Toluidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 2 | 3 |
| 1999 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Toluidines" by people in Profiles.
-
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102935.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases. FASEB J. 2020 08; 34(8):10132-10145.
-
Inhibition of porcine epidemic diarrhea virus (PEDV) replication by A77 1726 through targeting JAK and Src tyrosine kinases. Virology. 2020 12; 551:75-83.
-
Developmental exposure to the endocrine disruptor tolylfluanid induces sex-specific later-life metabolic dysfunction. Reprod Toxicol. 2019 10; 89:74-82.
-
Control of hyperglycemia in male mice by leflunomide: mechanisms of action. J Endocrinol. 2018 04; 237(1):43-58.
-
Inhibition of p70 S6 kinase activity by A77 1726 induces autophagy and enhances the degradation of superoxide dismutase 1 (SOD1) protein aggregates. Cell Death Dis. 2018 03 14; 9(3):407.
-
Dietary exposure to the endocrine disruptor tolylfluanid promotes global metabolic dysfunction in male mice. Endocrinology. 2015 Mar; 156(3):896-910.
-
Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia. 2014 Oct; 16(10):824-34.
-
The endocrine disrupting chemical tolylfluanid alters adipocyte metabolism via glucocorticoid receptor activation. Mol Endocrinol. 2013 Mar; 27(3):394-406.